Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 6 Summary of adverse events in the safety analysis set

From: Effect of subcutaneous tocilizumab treatment on work/housework status in biologic-naïve rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC study

  TCZ-SC group, n (%) csDMARDs-alone group, n (%)
n 358 336
AEs 127 (35.5) 99 (29.5)
Drug-related AEs 85 (23.7)
Serious AEs 32 (8.9) 11 (3.3)
Serious drug-related AEs 21 (5.9)
AEs leading to discontinuation of study treatment 33 (9.2) 28 (8.3)
Drug-related AEs leading to discontinuation of study treatment 29 (8.1)
  1. AE adverse event, csDMARD conventional synthetic disease-modifying antirheumatic drug, TCZ-SC tocilizumab by subcutaneous injection